## HélÃ"ne Péré

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3939937/publications.pdf

Version: 2024-02-01

25 papers 6,748 citations

759233 12 h-index 25 g-index

28 all docs

28 docs citations

times ranked

28

15534 citing authors

#	Article	IF	Citations
1	Persistent Coronavirus Disease 2019 (COVID-19) in an Immunocompromised Host Treated by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific Monoclonal Antibodies. Clinical Infectious Diseases, 2022, 74, 1706-1707.	5.8	14
2	Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature, 2022, 602, 671-675.	27.8	1,202
3	Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2. EBioMedicine, 2022, 77, 103934.	6.1	10
4	Prognostic Analysis of HPV Status in Sinonasal Squamous Cell Carcinoma. Cancers, 2022, 14, 1874.	3.7	8
5	Highly Sensitive Quantification of Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Sheds Light on its Potential Clinical Value. Clinical Infectious Diseases, 2021, 73, e2890-e2897.	5.8	92
6	Usefulness of Plasma SARS-CoV-2 RNA Quantification by Droplet-based Digital PCR to Monitor Treatment Against COVID-19 in a B-cell Lymphoma Patient. Stem Cell Reviews and Reports, 2021, 17, 296-299.	3.8	16
7	Episomal HPV16 responsible for aggressive and deadly metastatic anal squamous cell carcinoma evidenced in peripheral blood. Scientific Reports, 2021, 11, 4633.	3.3	4
8	Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nature Medicine, 2021, 27, 917-924.	30.7	617
9	Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature, 2021, 596, 276-280.	27.8	1,803
10	Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection. Nature Immunology, 2021, 22, 1428-1439.	14.5	110
11	No SARS-CoV-2 reinfection among staff health-care workers: Prospective hospital-wide screening		
	during the first and second waves in Paris. Journal of Clinical Virology, 2021, 145, 104999.	3.1	2
12	during the first and second waves in Paris. Journal of Clinical Virology, 2021, 145, 104999.  Circulating Ubiquitous RNA, A Highly Predictive and Prognostic Biomarker in Hospitalized Coronavirus Disease 2019 (COVID-19) Patients. Clinical Infectious Diseases, 2021, , .	5.8	3
12	Circulating Ubiquitous RNA, A Highly Predictive and Prognostic Biomarker in Hospitalized		
	Circulating Ubiquitous RNA, A Highly Predictive and Prognostic Biomarker in Hospitalized Coronavirus Disease 2019 (COVID-19) Patients. Clinical Infectious Diseases, 2021, , .  HPV circulating tumoral DNA quantification by dropletâ€based digital PCR: A promising predictive and prognostic biomarker for HPVâ€associated oropharyngeal cancers. International Journal of Cancer,	5.8	3
13	Circulating Ubiquitous RNA, A Highly Predictive and Prognostic Biomarker in Hospitalized Coronavirus Disease 2019 (COVID-19) Patients. Clinical Infectious Diseases, 2021, , .  HPV circulating tumoral DNA quantification by dropletâ€based digital PCR: A promising predictive and prognostic biomarker for HPVâ€associated oropharyngeal cancers. International Journal of Cancer, 2020, 147, 1222-1227.  Juvenile-Onset Recurrent Respiratory Papillomatosis Aggressiveness: In Situ Study of the Level of	5.8 5.1	3 65
13 14	Circulating Ubiquitous RNA, A Highly Predictive and Prognostic Biomarker in Hospitalized Coronavirus Disease 2019 (COVID-19) Patients. Clinical Infectious Diseases, 2021, , .  HPV circulating tumoral DNA quantification by dropletâ€based digital PCR: A promising predictive and prognostic biomarker for HPVâ€associated oropharyngeal cancers. International Journal of Cancer, 2020, 147, 1222-1227.  Juvenile-Onset Recurrent Respiratory Papillomatosis Aggressiveness: In Situ Study of the Level of Transcription of HPV E6 and E7. Cancers, 2020, 12, 2836.  HPV Detection in Head and Neck Squamous Cell Carcinomas: What Is the Issue? Frontiers in Oncology,	5.8 5.1 3.7	3 65 9
13 14 15	Circulating Ubiquitous RNA, A Highly Predictive and Prognostic Biomarker in Hospitalized Coronavirus Disease 2019 (COVID-19) Patients. Clinical Infectious Diseases, 2021, , .  HPV circulating tumoral DNA quantification by dropletâ€based digital PCR: A promising predictive and prognostic biomarker for HPVâ€associated oropharyngeal cancers. International Journal of Cancer, 2020, 147, 1222-1227.  Juvenile-Onset Recurrent Respiratory Papillomatosis Aggressiveness: In Situ Study of the Level of Transcription of HPV E6 and E7. Cancers, 2020, 12, 2836.  HPV Detection in Head and Neck Squamous Cell Carcinomas: What Is the Issue?. Frontiers in Oncology, 2020, 10, 1751.  Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science,	5.8 5.1 3.7 2.8	3 65 9 39

#	Article	IF	CITATIONS
19	Sequential SARS-CoV-2 IgG assays as confirmatory strategy to confirm equivocal results: Hospital-wide antibody screening in 3,569 staff health care workers in Paris. Journal of Clinical Virology, 2020, 132, 104617.	3.1	10
20	COVID-19–Related Collapsing Glomerulopathy in a Kidney Transplant Recipient. American Journal of Kidney Diseases, 2020, 76, 590-594.	1.9	37
21	HPV detection and genotyping of head and neck cancer biopsies by molecular testing with regard to the new oropharyngeal squamous cell carcinoma classification based on HPV status. Pathology, 2019, 51, 421-425.	0.6	12
22	Comment on "Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis". British Journal of Cancer, 2019, 120, 952-953.	6.4	2
23	Evaluation of the efficacy of the 4 tests (p16 immunochemistry, polymerase chain reaction, DNA, and) Tj ETQq1 cohort of 348 French squamous cell carcinomas. Human Pathology, 2018, 78, 63-71.	1 0.78431 2.0	4 rgBT /Over 31
24	HPV RNA CISH score identifies two prognostic groups in a p16 positive oropharyngeal squamous cell carcinoma population. Modern Pathology, 2018, 31, 1645-1652.	5.5	13
25	An unusual human papillomavirus type 82 detection in laryngeal squamous cell carcinoma: Case report and review of literature. Journal of Clinical Virology, 2012, 54, 190-193.	3.1	12